Transgenic animal models of neurodegenerative diseases and their application to treatment development.

Neurodegenerative disorders of the aging population affect over 5 million people in the US and Europe alone. The common feature is the progressive accumulation of misfolded proteins with the formation of toxic oligomers. Previous studies show that while in Alzheimer's disease (AD) misfolded amyloid-beta protein accumulates both in the intracellular and extracellular space, in Lewy body disease (LBD), Parkinson's disease (PD), Multiple System Atrophy (MSA), Fronto-Temporal dementia (FTD), prion diseases, amyotrophic lateral sclerosis (ALS) and trinucleotide repeat disorders (TNRD), the aggregated proteins accumulate in the plasma membrane and intracellularly. Protein misfolding and accumulation is the result of an altered balance between protein synthesis, aggregation rate and clearance. Based on these studies, considerable advances have been made in the past years in developing novel experimental models of neurodegenerative disorders. This has been in part driven by the identification of genetic mutations associated with familial forms of these conditions and gene polymorphisms associated with the more common sporadic variants of these diseases. Transgenic and knock out rodents and Drosophila as well as viral vector driven models of Alzheimer's disease (AD), PD, Huntington's disease (HD) and others have been developed, however the focus for this review will be on rodent models of AD, FTD, PD/LBD, and MSA. Promising therapeutic results have been obtained utilizing amyloid precursor protein (APP) transgenic (tg) models of AD to develop therapies including use of inhibitors of the APP-processing enzymes beta- and gamma-secretase as well as vaccine therapies.

[1]  R. Nicoll,et al.  Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. Trojanowski,et al.  Attenuated Neurodegenerative Disease Phenotype in Tau Transgenic Mouse Lacking Neurofilaments , 2001, The Journal of Neuroscience.

[3]  S. Gershon,et al.  Is the neuronal basis of Alzheimer's disease cholinergic or glutamatergic? , 1990, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  D. Selkoe,et al.  The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. , 2000, Biochemistry.

[5]  F. Grosveld,et al.  Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. , 1998, Science.

[6]  D. Borchelt,et al.  The Value of Transgenic Models for the Study of Neurodegenerative Diseases , 2000, Annals of the New York Academy of Sciences.

[7]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[8]  S. DeKosky,et al.  Structural correlates of cognition in dementia: quantification and assessment of synapse change. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[9]  Jürgen Götz,et al.  Tau and transgenic animal models , 2001, Brain Research Reviews.

[10]  S. Turner,et al.  Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695* , 2001, The Journal of Biological Chemistry.

[11]  J. Trojanowski,et al.  Mouse Model of Multiple System Atrophy α-Synuclein Expression in Oligodendrocytes Causes Glial and Neuronal Degeneration , 2005, Neuron.

[12]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism. , 2002, Biochemistry.

[13]  E. Masliah.  Recent advances in the understanding of the role of synaptic proteins in Alzheimer's Disease and other neurodegenerative disorders. , 2001, Journal of Alzheimer's disease : JAD.

[14]  L. Mucke,et al.  Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation , 2004, Nature Medicine.

[15]  J. Trojanowski,et al.  Selective Insolubility of α-Synuclein in Human Lewy Body Diseases Is Recapitulated in a Transgenic Mouse Model , 2001 .

[16]  S. Scheff,et al.  Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies , 2003, Neurobiology of Aging.

[17]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[18]  H. Geerts,et al.  Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. , 1999, The American journal of pathology.

[19]  E. Masliah.  The Role of Synaptic Proteins in Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[20]  J. Brion,et al.  Characterisation of cytoskeletal abnormalities in mice transgenic for wild-type human tau and familial Alzheimer's disease mutants of APP and presenilin-1 , 2004, Neurobiology of Disease.

[21]  L. Mucke,et al.  Levels and Alternative Splicing of Amyloid β Protein Precursor (APP) Transcripts in Brains of APP Transgenic Mice and Humans with Alzheimer's Disease (*) , 1995, The Journal of Biological Chemistry.

[22]  E. Masliah,et al.  The Role of Synaptic Proteins in the Pathogenesis of Disorders of the Central Nervous System , 1993, Brain pathology.

[23]  F. Doricchi,et al.  Attentional functions in multiple system atrophy and Parkinson's disease. , 1996, Journal of neurology, neurosurgery, and psychiatry.

[24]  B. Hyman,et al.  Nigral and Cortical Lewy Bodies and Dystrophic Nigral Neurites in Parkinson's Disease and Cortical Lewy Body Disease Contain α-synuclein Immunoreactivity , 1998, Journal of neuropathology and experimental neurology.

[25]  T. Hashikawa,et al.  Neurodegeneration with Tau Accumulation in a Transgenic Mouse Expressing V337M Human Tau , 2002, The Journal of Neuroscience.

[26]  S. Styren,et al.  Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer's disease , 1988, Neurobiology of Aging.

[27]  Y. Christen,et al.  Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. , 1999, Free radical biology & medicine.

[28]  P. Lansbury,et al.  Amyloid diseases: abnormal protein aggregation in neurodegeneration. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Kosik.  Tau protein and neurodegeneration , 1990, Molecular Neurobiology.

[30]  Akihiko Takashima,et al.  Formation of Filamentous Tau Aggregations in Transgenic Mice Expressing V337M Human Tau , 2001, Neurobiology of Disease.

[31]  Pico Caroni,et al.  Neuropathology in Mice Expressing Human α-Synuclein , 2000, The Journal of Neuroscience.

[32]  E. Masliah,et al.  Structural basis of the cognitive alterations in Alzheimer disease. , 1994 .

[33]  E. Masliah,et al.  Neurofibrillary Pathology in Transgenic Mice Overexpressing V717F β‐Amyloid Precursor Protein , 2001, Journal of neuropathology and experimental neurology.

[34]  Veerle Baekelandt,et al.  Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain* , 1999, The Journal of Biological Chemistry.

[35]  J. Hardy,et al.  Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP , 2001, Science.

[36]  M. Mallory,et al.  Early formation of mature amyloid‐β protein deposits in a mutant APP transgenic model depends on levels of Aβ1–42 , 2001, Journal of neuroscience research.

[37]  E. Masliah,et al.  Alpha‐synuclein in Lewy Body Disease and Alzheimer's Disease , 1999, Brain pathology.

[38]  G. V. Van Hoesen,et al.  Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. , 1984, Science.

[39]  P. Lansbury.  Evolution of amyloid: what normal protein folding may tell us about fibrillogenesis and disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[40]  D. Dickson,et al.  Analysis of tauopathies with transgenic mice. , 2001, Trends in molecular medicine.

[41]  H. Newbery,et al.  Of mice, men and motor neurons. , 2002, Trends in molecular medicine.

[42]  Bertrand Z. Yeung,et al.  Vulnerability of Dentate Granule Cells to Disruption of Arc Expression in Human Amyloid Precursor Protein Transgenic Mice , 2005, The Journal of Neuroscience.

[43]  W. Honer,et al.  Abnormal accumulation of NACP/alpha-synuclein in neurodegenerative disorders. , 1998, The American journal of pathology.

[44]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[45]  J. Trojanowski,et al.  “Fatal Attractions” of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders , 2000, Annals of the New York Academy of Sciences.

[46]  B. Hyman,et al.  APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.

[47]  W. Honer.  Pathology of presynaptic proteins in Alzheimer’s disease: more than simple loss of terminals , 2003, Neurobiology of Aging.

[48]  Robert H. Perry,et al.  Neurotransmitter enzyme abnormalities in senile dementia Choline acetyltransferase and glutamic acid decarboxylase activities in necropsy brain tissue , 1977, Journal of the Neurological Sciences.

[49]  Ted M. Dawson,et al.  Animal Models of PD Pieces of the Same Puzzle? , 2002, Neuron.

[50]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[51]  J. Brion.  The role of neurofibrillary tangles in Alzheimer disease. , 1998, Acta Neurologica Belgica.

[52]  H. Zoghbi,et al.  Insights from mouse models into the molecular basis of neurodegeneration. , 2000, Annual review of physiology.

[53]  P. Heutink,et al.  Chasing genes in Alzheimer’s and Parkinson’s disease , 2004, Human Genetics.

[54]  C. Marsden,et al.  Cognitive performance in multiple system atrophy. , 1992, Brain : a journal of neurology.

[55]  D. Borchelt,et al.  Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins , 1997, Neuron.

[56]  R. D. Williams,et al.  Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Lovestone,et al.  Neurofibrillary tangles and tau phosphorylation. , 2001, Biochemical Society symposium.

[58]  Ronald L Klein,et al.  Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. , 2002, Human gene therapy.

[59]  A. Aguzzi,et al.  Transgenic and knockout mice in the study of neurodegenerative diseases , 1996, Journal of Molecular Medicine.

[60]  W. Weiner,et al.  From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease , 2003, Current opinion in neurology.

[61]  J. Hardy,et al.  The presenilins and Alzheimer's disease. , 1997, Human molecular genetics.

[62]  D. Dickson,et al.  Alzheimer's disease. A double-labeling immunohistochemical study of senile plaques. , 1988, The American journal of pathology.

[63]  A. Goate,et al.  Molecular genetics of Alzheimer’s disease , 2004, Current psychiatry reports.

[64]  Makoto Hashimoto,et al.  Transgenic Models of α‐Synuclein Pathology , 2003 .

[65]  Wen-Lang Lin,et al.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.

[66]  Takeshi Iwatsubo,et al.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia , 1998, Cell Death and Differentiation.

[67]  Allan I. Levey,et al.  Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.

[68]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[69]  P. Lansbury,et al.  Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson’s disease? , 2000, Nature Cell Biology.

[70]  T. Sherer,et al.  Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[71]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[72]  T. Albright,et al.  Immunoreactivity of CD45, a protein phosphotyrosine phosphatase, in Alzheimer's disease , 2004, Acta Neuropathologica.

[73]  J. Brion,et al.  Transgenic expression of the shortest human tau affects its compartmentalization and its phosphorylation as in the pretangle stage of Alzheimer's disease. , 1999, The American journal of pathology.

[74]  J. Trojanowski,et al.  Age-dependent induction of congophilic neurofibrillary tau inclusions in tau transgenic mice. , 2001, The American journal of pathology.

[75]  P. Silver,et al.  Polyglutamine Expansions Proteolysis, Chaperones, and the Dangers of Promiscuity , 2000, Neuron.

[76]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.

[77]  C. van Broeckhoven,et al.  Molecular genetics of Alzheimer's disease. , 1998, Annals of medicine.

[78]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[79]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[80]  M. Shapiro,et al.  Impaired learning and LTP in mice expressing the carboxy terminus of the Alzheimer amyloid precursor protein , 1997, Nature.

[81]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[82]  E. Masliah,et al.  An antibody against phosphorylated neurofilaments identifies a subset of damaged association axons in Alzheimer's disease. , 1993, The American journal of pathology.

[83]  S. Scheff,et al.  Alzheimer's disease-related synapse loss in the cingulate cortex. , 2001, Journal of Alzheimer's disease : JAD.

[84]  R. A. Crowther,et al.  Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein , 2000, Acta Neuropathologica.

[85]  Howard J. Federoff,et al.  Behavioral and Neurochemical Effects of Wild-Type and Mutated Human α-Synuclein in Transgenic Mice , 2002, Experimental Neurology.

[86]  Bin Zhang,et al.  Amyotrophic Lateral Sclerosis/Parkinsonism Dementia Complex: Transgenic Mice Provide Insights into Mechanisms Underlying a Common Tauopathy in an Ethnic Minority on Guam , 2002, Experimental Neurology.

[87]  Hideo Fujiwara,et al.  Hyperphosphorylation and insolubility of α‐synuclein in transgenic mouse oligodendrocytes , 2002 .

[88]  G. Schellenberg,et al.  Tau is a candidate gene for chromosome 17 frontotemporal dementia , 1998, Annals of neurology.

[89]  N. Shibata.  Transgenic mouse model for familial amyotrophic lateral sclerosis with superoxide dismutase‐1 mutation , 2001, Neuropathology : official journal of the Japanese Society of Neuropathology.

[90]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[91]  B. Sommer,et al.  Expression of APP in transgenic mice: a Comparison of neuron-specific promoters , 1996, Neurobiology of Aging.

[92]  P. Lansbury,et al.  Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. , 2001, Biochemistry.

[93]  P. Davies,et al.  Characterization of Pathology in Transgenic Mice Over-Expressing Human Genomic and cDNA Tau Transgenes , 2000, Neurobiology of Disease.

[94]  G. Higgins,et al.  Transgenic mouse models of Alzheimer's disease: phenotype and application , 2003, Behavioural pharmacology.

[95]  Beate Gerstbrein,et al.  Dying for a cause: invertebrate genetics takes on human neurodegeneration , 2003, Nature Reviews Genetics.

[96]  A. Aguzzi,et al.  Neurodegeneration: Of (transgenic) Mice and Men , 1998 .

[97]  M. Citron,et al.  Both Familial Parkinson’s Disease Mutations Accelerate α-Synuclein Aggregation* , 1999, The Journal of Biological Chemistry.

[98]  Kevin Cox,et al.  Quantitative analysis of a vulnerable subset of pyramidal neurons in Alzheimer's disease: I. Superior frontal and inferior temporal cortex , 1990, The Journal of comparative neurology.

[99]  R. Nitsch,et al.  Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. , 2001, The Journal of biological chemistry.

[100]  Michael J. Rowan,et al.  Amyloid-β oligomers: their production, toxicity and therapeutic inhibition , 2001 .

[101]  J. Streffer,et al.  Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.

[102]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[103]  Bin Zhang,et al.  Age-Dependent Emergence and Progression of a Tauopathy in Transgenic Mice Overexpressing the Shortest Human Tau Isoform , 1999, Neuron.

[104]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[105]  B. Hyman,et al.  Aβ Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse , 1997, The Journal of Neuroscience.

[106]  M. Staufenbiel,et al.  Transgenic Mouse Models of Alzheimer's Disease , 2000, Annals of the New York Academy of Sciences.

[107]  V. Blanchard,et al.  Increased tau phosphorylation but absence of formation of neurofibrillary tangles in mice double transgenic for human tau and Alzheimer mutant (M146L) presenilin-1 , 2002, Neuroscience Letters.

[108]  Nancy A. Jenkins,et al.  Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[109]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[110]  T. Bliss,et al.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice , 1999, Nature Neuroscience.

[111]  R. Nitsch,et al.  Tau Filament Formation in Transgenic Mice Expressing P301L Tau* , 2001, The Journal of Biological Chemistry.

[112]  R. Nitsch,et al.  Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils , 2001, Science.

[113]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[114]  Ronald C. Petersen,et al.  Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17 , 1998, Nature.

[115]  M. Chesselet,et al.  Alpha-synuclein and transgenic mouse models , 2004, Neurobiology of Disease.

[116]  L. Murri,et al.  Causative and susceptibility genes for Alzheimer’s disease: a review , 2003, Brain Research Bulletin.

[117]  S. Tabrizi,et al.  Mouse models as a tool for understanding neurodegenerative diseases , 2003, Current opinion in neurology.

[118]  G K Wilcock,et al.  The differential involvement of subcortical nuclei in senile dementia of Alzheimer's type. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[119]  D. Selkoe,et al.  The Role of APP Processing and Trafficking Pathways in the Formation of Amyloid β‐Protein a , 1996 .

[120]  L. Mucke,et al.  Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[121]  F. LaFerla,et al.  Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s disease , 2003, Neurobiology of Aging.

[122]  T. Hashikawa,et al.  Tau filament formation and associative memory deficit in aged mice expressing mutant (R406W) human tau , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[123]  L. Mucke,et al.  Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. , 2000, Science.

[124]  M. Beal,et al.  Experimental models of Parkinson's disease , 2001, Nature Reviews Neuroscience.

[125]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[126]  E. Masliah,et al.  Neurodegenerative Alzheimer-like pathology in PDAPP 717V-->F transgenic mice. , 1998, Progress in brain research.